Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 784.13 732.81 717.34 7.00% 9.31%
EBITDA 194.95 153.53 184.85 26.98% 5.46%
Op. profit margin(%) 20.33 15.39 21.29 32.06% -4.53%
Net Profit 19.96 -8.66 17.85 330.34% 11.78%
EPS 0.99 -0.43 0.89 330.23% 11.24%
* Consolidated data
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 9.91 6.90 5.01 43.67% 97.99%
EBITDA 5.07 3.45 2.46 46.88% 105.91%
Op. profit margin(%) 49.62 44.90 47.17 10.51% 5.19%
Net Profit 3.01 2.02 1.76 49.21% 71.11%
EPS 5.52 3.70 4.53 49.08% 21.66%
* Consolidated data
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 514.39 477.37 436.55 7.75% 17.83%
EBITDA 266.91 233.93 180.46 14.10% 47.91%
Op. profit margin(%) 49.41 46.43 38.97 6.43% 26.80%
Net Profit 86.72 74.50 34.53 16.40% 151.14%
EPS 3.51 3.02 1.80 16.23% 95.00%
* Standalone data
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 0.11 9.46 -2.37 -98.88% 104.49%
EBITDA -1.21 9.26 -2.54 -113.10% 52.23%
Op. profit margin(%) -1142.18 97.85 107.24 -1267.26% -1165.06%
Net Profit -1.22 9.24 -2.55 -113.24% 52.00%
EPS -2.04 15.41 -4.08 -113.24% 50.00%
* Standalone data
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 514.39 477.37 436.55 7.75% 17.83%
EBITDA 266.91 233.93 180.46 14.10% 47.91%
Op. profit margin(%) 49.41 46.43 38.97 6.43% 26.80%
Net Profit 86.72 74.50 34.53 16.40% 151.14%
EPS 3.51 3.02 1.80 16.23% 95.00%
* Standalone data
460.75
-1.23%
Aptus Pharma Ltd - 544529 - Financial Results For The Half Year Ended 30Th September,2026
BSE India
Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, 20th October, 2026 inter alia considered and approved the following: The unaudited financial results of the company for the half year ended September, 30, 2026 along with the Limited Review Report issued by the Statutory Auditors have been approved by the Board of Directors. A copy of the same is enclosed herewith as annexure. Further, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading Regulations), 2015 and the Company''s Code of Conduct for Prohibition of insider trading , the "Trading Window" for trading in the shares of the Company will open from 23rd October, 2026 for the designated persons and their immediate relatives.
460.75
-1.23%
Aptus Pharma Ltd - 544529 - Board Meeting Outcome for Outcome Of Board Meeting Held On …
BSE India
Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today, i.e., Tuesday, October 20, 2026, inter alia, considered and approved the following: The Unaudited Financial Results of the Company for the half year ended September 30, 2026, along with the Limited Review Report issued by the Statutory Auditors, have been approved by the Board of Directors. The copy of the same is enclosed herewith as Annexure. Further, in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Company''s Code of conduct for Prohibition of Insider Trading, the "Trading Window" for trading in the shares of the Company will open from 23 October, 2026. for the Designated Persons and their immediate relatives.
36.55
2.90%
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 136.04 92.72 68.84 46.72% 97.61%
EBITDA 5.46 11.19 8.84 -51.16% -38.16%
Op. profit margin(%) 3.34 11.69 12.68 -71.46% -73.69%
Net Profit 4.66 3.61 3.56 29.19% 31.12%
EPS 1.54 1.19 1.21 29.41% 27.27%
* Standalone data
Sep 2026Jun 2026Sep 2025QoQ%YoY%
Revenue/Sales 0.00 0.00 0.00 - -
EBITDA -0.05 0.28 -0.04 -118.76% -17.12%
Net Profit -0.25 0.08 -0.04 -412.45% -508.98%
EPS -0.58 0.19 -0.09 -402.63% -511.70%
* Standalone data